Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04141462
Recruiting Not applicable

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

NCT04141462 · tracked via the Priya Life Science France tracker
Sponsor
Centre Georges Francois Leclerc
Phase
Not applicable
Started
2019-10-07
Last updated
2026-04-03

Condition(s) studied

CancerGenetic Predisposition

Investigational drug(s) / intervention(s)

blood sample

blood sample: blood test

Study summary

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Index case: 1. Major or minor patient 2. Histological or cytological evidence of malignant tumor diagnosis 3. Patient with cancer before age 40 (or before age 30 for breast cancer). 4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned 5. Patient affiliated to a social security scheme 6. Signature of Informed Consent EXTRICAN 7. Availability of a tumor sample if needed secondary functional studies 8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents) 9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person) Related: 1. Major or minor patient 2. Histological or cytological evidence of the diagnosis of malignant tumor if 3. Patient affiliated to a social security scheme 4. Signing informed consent EXTRICAN Exclusion Criteria: Index and related case: 1. Refusal of the patient participation 2. Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study 3. Patient under guardianship, curatorship or safeguard of justice 4. Pregnant woman

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
CHRU Jean Minjoz Besançon France Not Yet Recruiting
Centre Georges-François Leclerc Dijon France Recruiting
CHU de Dijon Dijon France Not Yet Recruiting
CHU de Reims Reims France Not Yet Recruiting
Polyclinique de Courlancy Reims France Not Yet Recruiting
CH de Troyes Troyes France Not Yet Recruiting

More Centre Georges Francois Leclerc trials in France

Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions Recruiting
Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine Recruiting
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors Active, not recruiting
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM) Recruiting
Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer. Active, not recruiting

Other trials for the same condition

Deployment of Teleconsulting in Geriatric Oncology for Older Patients Recruiting
COsegregation of VARiants in Panel of Genes Recruiting
Vulnerability and Risk of Neuropathic Pain in Cancer Recruiting
Description of the Stroma of Solid Tumors (DISTRO) Active, not recruiting
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04141462 on ClinicalTrials.gov ↗ ← All trials in France